GON Block With Bupivacaine Not Superior To Metoclopramide For Migraine Treatment: Study
- byDoctor News Daily Team
- 08 July, 2025
- 0 Comments
- 0 Mins
USA: Greater occipital nerve blocks (GONB) with bupivacaine is not effective as IV metoclopramide for the first-line migraine treatment in the emergency department (ED), suggests a recent study in the journal Headache.
GONB are increasingly been used for the treatment of acute migraine. Benjamin W. Friedman, Albert Einstein College of Medicine, Montefiore, Bronx, NY, USA, and colleagues conducted a double‐dummy, double‐blind, parallel‐arm, non‐inferiority randomized controlled trial in 2 EDs to determine whether GONB was as effective as intravenous metoclopramide for migraine.
The researchers screened 1358 patients for participation, of those 99 were included. 99 patients with migraine of moderate or severe intensity were randomized to receive bilateral GONB with each side administered 3 mL of bupivacaine 0.5% (n=51) or metoclopramide 10 mg IV (n=48), the putative standard of care. They were followed for over a 2.5‐year of the study period.
The primary outcome was improvement in pain on a 0‐10 scale between time 0 and 1 hour later. Secondary outcomes included sustained headache relief, defined as achieving and maintaining for 48 hours a headache level of mild or none without the use of additional analgesic medication, and the use of rescue medication in the ED.
Also Read: Timolol eyedrops promising treatment for acute migraine: JAMA
Key findings of the study include:
Patients who received the GONB reported mean improvement of 5.0 while those who received metoclopramide reported a larger mean improvement of 6.1.
The 95% CI for the between group difference of −1.1 was −2.3, 0.1.
Sustained headache relief was reported by 22% of GONB and 38% of metoclopramide patients.
Of the 51 GONB patients 33% required rescue medication in the ED vs 17% metoclopramide patients.
An adverse event was reported by 31% of GONB patients and 38% metoclopramide patients.
Based on the findings the authors concluded that GONB with bupivacaine was not as efficacious as IV metoclopramide for the first‐line treatment of migraine in the ED.
Also Read:Green light significantly reduces headache frequency in migraine: Study
"A Randomized, Double‐Dummy, Emergency Department‐Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine," is published in the journal Headache.
DOI: https://headachejournal.onlinelibrary.wiley.com/doi/abs/10.1111/head.13961
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Tags:
Recent News
Eli Lilly plans to build new USD 3 billion facilit...
- 04 November, 2025
Rajkot Maternity Hospital CCTV Leak: How a simple...
- 04 November, 2025
Gland Pharma profit rises 12 percent to Rs 184 cro...
- 04 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!